A study has shown that intravitreal ranibizumab injections for neovascular age-related macular degeneration yielded similar outcomes in phakic and pseudophakic eyes.[/vc_column_text][/vc_column]
Phakic and pseudophakic patients received three monthly loading dose injections of ranizibumab and were then treated on an as needs basis.
At final follow-up, mean BCVA was 0.75 in the phakic group and 0.74 in the pseudophakic group. Both improvements were statistically significant. Central macular thickness decreased significantly in both groups.
